Galazolin, drops 0.1% 10 ml

A vasoconstrictor for local use in ENT practice. Alpha-adrenomimetic of the group of imidazole derivatives. In low concentrations it acts on α2-adrenoreceptors, in high concentrations it acts on α1-adrenoreceptors.

In local application causes constriction of blood vessels, which leads to reduction of edema and hyperemia of mucous membranes of the nasopharynx, reduces nasal discharge, facilitates nasal breathing in rhinitis.

The action of the drug starts within 5-10 min and lasts for 5-6 h when used in the form of nasal drops and for 10 h when used in the form of nasal gel.

Indications

acute rhinitis of viral or bacterial origin;
allergic rhinitis;
acute sinusitis;
chronic sinusitis in the acute phase;
hay fever;
otitis media (to reduce swelling of the mucous membrane of the nasopharynx and restore patency of the Eustachian tube).

Pharmacological effect

Vasoconstrictor drug for local use in ENT practice. Alpha adrenergic agonist from the group of imidazole derivatives. In low concentrations it acts on α2-adrenergic receptors, in high concentrations it acts on α1-adrenergic receptors.

When applied topically, it causes a narrowing of blood vessels, which leads to a reduction in swelling and hyperemia of the mucous membranes of the nasopharynx, reduces the amount of nasal discharge, and facilitates nasal breathing in case of rhinitis.

The effect of the drug begins within 5-10 minutes and lasts for 5-6 hours when used in the form of nasal drops and for 10 hours when used in the form of a nasal gel.

Special instructions

Long-term use of Galazolin leads to a weakening of its effect, the development of atrophy of the nasal mucosa and reactive hyperemia with drug-induced rhinitis.

Active ingredient

Xylometazoline

Composition

1 ml:

– xylometazoline hydrochloride 500 mcg or 1 mg

Excipients:

sodium hydrogen phosphate dodecahydrate,

sodium dihydrogen phosphate monohydrate,

sodium chloride,

disodium edetate,

benzalkonium chloride,

sorbitol,

purified water.

Pregnancy

Galazolin should be used only after assessing the risk-benefit ratio for the fetus and mother.

It is not allowed to exceed the recommended doses during pregnancy and lactation (breastfeeding).

Contraindications

hypersensitivity to the components of the drug;
atrophic rhinitis;
angle-closure glaucoma;
arterial hypertension;
severe atherosclerosis;
tachycardia;
hyperthyroidism (for nasal drops);
surgical intervention on the meninges (history);
simultaneous use of MAO inhibitors and a period of 14 days after the end of their use;
simultaneous use of tricyclic antidepressants;
pregnancy;
children up to 6 years of age (for 0.1% nasal drops) and up to 2 years (for 0.05% nasal drops);
children up to 12 years of age (for 0.1% nasal gel) and up to 3 years (for 0.05% nasal gel).

The drug should be used with caution during lactation, with diabetes mellitus, with angina pectoris III-IV functional class, prostatic hyperplasia, pheochromocytoma (for nasal drops), with hyperthyroidism (for nasal gel).

Side Effects

Local reactions: sometimes – burning, dry nasal mucosa, sneezing; rarely – reactive hyperemia (a strong feeling of nasal congestion after the effect of the drug wears off).

Other: sometimes with local overdose – tachycardia, increased blood pressure; very rarely – anxiety, insomnia, fatigue, headache, nausea.

Storage conditions

The drug should be stored in a place protected from light, out of reach of children, at a temperature of 15° to 25°C.

Shelf life

3 years

Manufacturer

Polfa Warsaw Pharmaceutical Plant, Poland